|Bid||50.48 x 300|
|Ask||53.57 x 100|
|Day's Range||54.27 - 55.81|
|52 Week Range||45.31 - 71.32|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Seattle Genetics Inc (NASDAQ:SGEN) files its latest 10-K with SEC for the fiscal year ended on December 31, 2017.
The Bothell, Washington-based company said it had a loss of 41 cents per share. The results surpassed Wall Street expectations. The average estimate of nine analysts surveyed by Zacks Investment Research ...
Seattle Genetics (SGEN) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.
Intercept, Seattle Genetics and Corcept rose above the froth Thursday — popping on key drug, merger and earnings news.
Cascadian Therapeutics, Inc. (NASDAQ:CASC) is the big mid-week winner its acquisition by Seattle Genetics, Inc. (NASDAQ:SGEN). On Wednesday, January 31st, Cascadian announced that it will be acquired by Seattle Genetics. The deal will see the latter pick up the former at $10 a share, valuing Cascadian at just shy of $614 million based on current […] The post Cascadian Therapeutics Scores Big On Seattle Genetics Acquisition appeared first on Market Exclusive.
While companies like AbbVie (ABBV) were in focus on 4Q earnings results, Ablynx was in the news with the company agreeing to be acquired by French pharma giant, Sanofi.
Shares of Cascadian Therapeutics Inc (USA) (NASDAQ:CASC) surged as much as 72% after agreeing to be acquired by Seattle Genetics, Inc. (NASDAQ:SGEN) for $10 per share, a 69% premium over the prior closing price.
Cascadian Therapeutics saw its shares absolutely skyrocket on Wednesday after it was announced that Seattle Genetics would be acquiring the company. This is far and away the top-performing stock in Wednesday’s ...
Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Microsoft Corporation (NASDAQ: MSFT ) stock gained ...
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.
Seattle Genetics (SGEN) is witnessing robust growth for its sole marketed product, Adcetris. However, over dependence on the same is a concern amid rising competition.
In January 2018, the U.S. FDA (Food and Drug Administration) accepted Novartis’s (NVS) supplemental biologics license application (or SBLA) for Kymriah suspension for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (or DLBCL) who are not candidates for autologous stem cell transplant (or ASCT). The U.S. FDA granted Novartis’s sBLA for priority review. Also, the European Medicines Agency (or EMA) granted accelerated assessment to the marketing authorization application (or MAA) for Novartis’s Kymriah for the treatment of children and young adults with relapsed or refractory B-cell acute lymphoblastic leukemia (or ALL) and also for adults with relapsed or refractory DLBCL who are not candidates for ASCT.
European Commission extend the current conditional marketing authorization for an expanded indication of Adectris of Seattle Genetics (SGEN) and partner Takeda.